Could an antibiotic help reverse fatty liver? new trial launches
NCT ID NCT07381257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a gut-acting antibiotic called rifaximin-α can reduce liver fat in people with metabolic fatty liver disease (MASLD). About 60 adults will take either the drug or just follow diet and exercise advice for 24 weeks. The goal is to see if the drug safely lowers liver fat and helps understand how gut bacteria affect the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changzheng Hospital, Naval Medical University, shanghai, China
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Seaweed extract may tackle fatty liver Disease—A trial puts it to the test
- Can Weight-Loss surgery rewire the Liver's energy engine?
- Wheat sensitivity linked to fatty liver? a new study investigates
- Could a common sugar fuel liver damage?
- Could a common b vitamin tame fatty liver?